SAN FRANCISCO, July 31, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company's financial condition, revenue...
Hence then, the article about adma august 10 2026 deadline adma biologics inc investors have opportunity to lead class action lawsuit hbss was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS )
Also on site :
- Kevin Warsh’s first big press conference shines a spotlight on confusion over how the Fed actually measures inflation
- Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
- EA expect their $55 billion sale to Saudi Arabia and private equity firms to close next week, with "all regulatory approvals required" in place